Gt biopharma provides second quarter 2021 business update

Beverly hills, calif., aug. 13, 2021 /prnewswire/ -- gt biopharma, inc. ("gt biopharma" or the "company") (nasdaq: gtbp), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the company's proprietary natural killer (nk) cell engager (trike®) protein biologic technology platform, today provided a general business update of events in the second quarter ending june 30, 2021.
GTBP Ratings Summary
GTBP Quant Ranking